medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Number 3

<< Back Next >>

Ann Hepatol 2012; 11 (3)

Does the persistently normal aminotransferase levels in hepatitis C still have relevance?

Méndez-Navarro J, Dehesa-Violante M

Language: English
References: 15
Page: 412-414
PDF size: 62.68 Kb.


Text Extraction

Dear Editor,
About one third of patients with chronic hepatitis C (HCV) have normal levels of aminotransferases (ALT). Most of these patients have mild disease with lower histological fibrosis, although some may progress to advanced fibrosis and cirrhosis.


REFERENCES

  1. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002; 36(S1): S179-S184.

  2. Hui CK, Belaye T, Montegrande K, Wright T. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminases. J Hepatol 2003; 38: 511-7.

  3. Calvaruso V, Craxi A. Implication of normal liver enzymes in liver disease. J Viral Hepat 2009; 16: 529-36.

  4. Shiffman ML, Diago M, Pockros P, Prati D, Rodríguez-Torres M, Zeuzem S, et al. Chronic hepatitis C in Patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol 2006; 4: 645-52.

  5. Zapata R. Clinical approach to the patient with chronic hepatitis C infection and normal aminotransferases. Ann Hepatol 2010; 9: S72-S79.

  6. Mangia A, Spinzi G, Vuturo O, Pazienza V, Iacobellis A, Piattelli M, et al. Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study. Aliment Pharmacol Ther 2004; 19: 331-7.

  7. Hoofnagle J, Seeff L. Peginterferon and Ribavirin for chronic hepatitis C. N Engl J Med 2006; 355: 2444-51.

  8. Mendez-Navarro J, Chirino RA, Corey KE, Gorospe EC, Zheng H, Moran S, Juarez JA, et al. A randomized controlled trial of double vs. triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients. Dig Dis Sci 2010; 55: 2629-35.

  9. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, et al. Peginterferon Alfa-2a (40 Kilodaltons) and Ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724-32.

  10. Puoti C, Pellicelli AM, Romano M, et al. Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon α-2a and ribavirin: a multicentric study. Liver Int 2009; 29: 1479-84.

  11. Sixtos-Alonso S, Avalos-Martinez R, Chavez-Ayala, Garcia- Juarez I, Dominguez-Lopez A, Dehesa-Violante M, et al. (1087) Distribution of Interleukine 28B genetic variants and association with the viral response to antiviral treatment in Mexican patients with chronic hepatitis C. AASLD Abstracts. Hepatology 2011; 54 (Suppl.): 877A.

  12. Ghany MG, Strader D, Thomas D, Seeff LB. Diagnosis, management and treatment of hepatitis C: an update. AASLD practice guidelines. Hepatology 2009; 49: 1335-74.

  13. Latin American Association for the Study of the Liver Practice Guidelines. Diagnosis, management, and treatment of hepatitis C. Ann Hepatol 2010; 9(Suppl. 1): S8-S26.

  14. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.

  15. Akkaya O, Kiyici M, Yilmaz Y, Ulukaya E, Yerci O. Clinical significance of activity of ALT enzyme in patients with hepatitis C virus. World J Gastroenterol 2007; 13: 5481-5.




2020     |     www.medigraphic.com